Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

iPad monitoring system to improve patient care

Innovation

An innovative iPad-based early-warning system for patient monitoring will be rolled out across Oxfordshire hospitals thanks to a £550,000 funding boost.

The System for Electronic Notes Documentation (SEND) project is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, a collaboration between Oxford University Hospitals and Oxford University, won funding from the Safer Hospitals, Safer Wards NHS Technology Fund. The SEND project uses the latest computer tablet technology to record and evaluate patients’ vital signs, replacing traditional paper charts. It will help alert medical staff to early patient deterioration quickly and reliably, and allow that data to be shared with specialists across the hospital sites.

Read more

(NIHR Oxford Biomedical Research Centre website)

 Related news: iPads and robots will improve patient monitoring

(OUH Trust website)

Similar stories

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

Coronavirus COVID-19 Innovation Research

Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets

Coronavirus COVID-19 Innovation Research

New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.

QUOD enters partnership with Evotec

General Innovation Research

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.